Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 17/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893290 | 0.89 | CYP3A4 (0.81) | CYP3A4CYP2C9MAOACYP2D6 | |
| SCHEMBL4895217 | 0.86 | MAOA (0.81) | CYP3A4CYP2C9MAOACYP2D6 | |
| SCHEMBL4891794 | 0.86 | MAOA (1.00) | CYP3A4CYP2C9MAOACYP2D6 | |
| SCHEMBL4887857 | 0.85 | MAOA (1.00) | CYP3A4CYP2C9MAOACYP2D6 | |
| SCHEMBL4897434 | 0.85 | MAOA (0.75) | CYP3A4CYP2C9MAOACYP2D6 | |
| SCHEMBL4885180 | 0.85 | MAOA (0.79) | CYP3A4CYP2C9MAOACYP2D6 | |
| SCHEMBL4896038 | 0.84 | MAOA (0.74) | CYP3A4CYP2C9MAOACYP2D6 | |
| SCHEMBL4895902 | 0.84 | MAOA (0.74) | CYP3A4CYP2C9MAOACYP2D6 | |
| SCHEMBL1393082 | 0.84 | CYP3A4 (0.72) | CYP3A4CYP2C9MAOACYP2D6 | |
| SCHEMBL1393085 | 0.84 | CYP3A4 (0.72) | CYP3A4CYP2C9MAOACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021012-A1 | 3-[4-{6-Substituted Alkanoyl Pyridin-3-Yl}-3-Phenyl]-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones As Antibacterial Agents | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | US | disclosed |
| US-20080021012-A1 | 3-[4-{6-Substituted Alkanoyl Pyridin-3-Yl}-3-Phenyl]-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones As Antibacterial Agents | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021012-A1 | 3-[4-{6-Substituted Alkanoyl Pyridin-3-Yl}-3-Phenyl]-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones As Antibacterial Agents | MRPL21, ARG1, OXA1L | CYP3A4 269/4885CYP2C9 99/4885MAOA 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.